Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population.
Cancer in people with multidrug-resistant HIV / Clemente, T.; Pontillo, D.; Malagnino, V.; Calza, L.; Di Biagio, A.; Cenderello, G.; Lolatto, R.; Manzillo, E.; Moioli, M. C.; De Socio, G. V.; Castagna, A.; Spagnuolo, V.. - In: AIDS. - ISSN 0269-9370. - 38:12(2024), pp. 1801-1806. [10.1097/QAD.0000000000003952]
Cancer in people with multidrug-resistant HIV
Clemente T.;Castagna A.;Spagnuolo V.
2024-01-01
Abstract
Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
